Defining Prognostic Biomarkers and Optimal Adjuvant Treatment for Gynecologic Cancer
- PMID: 28586944
- DOI: 10.1016/j.ijrobp.2017.01.014
Defining Prognostic Biomarkers and Optimal Adjuvant Treatment for Gynecologic Cancer
Comment on
-
Prognostic importance of human papillomavirus (HPV) and p16 positivity in squamous cell carcinoma of the vulva treated with radiotherapy.Gynecol Oncol. 2016 Aug;142(2):293-8. doi: 10.1016/j.ygyno.2016.05.019. Epub 2016 Jun 3. Gynecol Oncol. 2016. PMID: 27210818
-
Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial.Lancet Oncol. 2016 Aug;17(8):1114-1126. doi: 10.1016/S1470-2045(16)30120-6. Epub 2016 Jul 7. Lancet Oncol. 2016. PMID: 27397040 Clinical Trial.
-
Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis.Gynecol Oncol. 2016 Nov;143(2):294-301. doi: 10.1016/j.ygyno.2016.08.317. Epub 2016 Aug 17. Gynecol Oncol. 2016. PMID: 27542967 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
